Ergothioneine composition and application thereof in whitening products

Abstract

The invention belongs to the technical field of nutritional compositions or cosmetics, and particularly relates to an ergothioneine composition and application of the ergothioneine composition in whitening products. The ergothioneine composition disclosed by the invention is prepared from glabridin and L-ergothioneine, wherein the mass ratio of the glabridin to the L-ergothioneine in the composition is 1 to (1 to 30). Experimental verification shows that the ergothioneine composition provided by the invention has the following three core effects: 1, the ergothioneine composition can effectively reduce the level of malondialdehyde (MDA) and exert an excellent anti-oxidation effect; 2, the tyrosinase activity can be obviously inhibited, and melanin generation is reduced from the source; and thirdly, the skin melanin index can be reduced, the whitening effect is realized, and the composition can be widely applied to preparation of cosmetics, health care products, food and medicines with antioxidant or whitening effects.

Description

Technical Field

[0001] This invention belongs to the field of nutritional compositions or cosmetics technology, specifically relating to an ergothioneine composition and its application in whitening products. Background Technology

[0002] In the field of whitening and antioxidant technology, existing products mostly rely on a single active ingredient to exert their effects, but they generally suffer from limitations in efficacy or application defects. For example, although hydroquinone can directly inhibit melanocyte activity, its cytotoxicity is strong, and long-term use can easily lead to skin irritation, uneven pigmentation, or even contact dermatitis, and its use has been restricted in many countries. Kojic acid exerts its whitening effect by competitively inhibiting tyrosinase, but its chemical structure is unstable and easily decomposes and becomes ineffective under light, high temperature, or alkaline environments, making it difficult to meet product shelf-life requirements. Niacinamide, as a popular whitening ingredient in recent years, can block melanin transport, but it causes intolerance problems such as redness and stinging in some sensitive skin types, and requires a high concentration to show effects. Although vitamin C and its derivatives have the ability to reduce melanin, they are easily oxidized, requiring additional stabilizers to be added to product formulations, and their transdermal absorption efficiency is low, affecting actual efficacy. In addition, most traditional whitening ingredients only target a single link in melanin production, transport, or reduction, failing to meet consumers' scenario-based application needs for both "antioxidant + whitening."

[0003] In the field of antioxidants, free radical damage is one of the core causes of skin aging and increased pigmentation. Malondialdehyde (MDA), as an important product of lipid peroxidation, directly reflects the degree of oxidative damage to the skin. Existing antioxidant ingredients such as vitamin E and coenzyme Q10 can scavenge some free radicals, but they are insufficient in terms of scavenging efficiency, targeting, and compatibility with whitening ingredients, making it difficult to simultaneously achieve the multiple effects of reducing MDA levels, inhibiting melanin production, and improving skin tone. Therefore, developing a "antioxidant + whitening" compound ingredient with high stability, low irritation, and multi-target synergistic effects has become a key direction for technological breakthroughs in the industry.

[0004] Ergothioneine, a natural sulfur-containing imidazole amino acid, is a highly effective antioxidant that has garnered significant attention in recent years. Its unique chemical structure allows it to penetrate cell membranes, target and eliminate intracellular reactive oxygen species (ROS), reduce lipid peroxidation, significantly lower MDA levels, protect mitochondrial function, delay skin photoaging, and exhibits good biocompatibility with no skin irritation. Glycyrrhizin, on the other hand, is a natural active ingredient extracted from glycyrrhiza plants. It competitively inhibits tyrosinase activity, reducing melanin production at its source, while also possessing anti-inflammatory and soothing effects, alleviating redness and sensitivity caused by external stimuli.

[0005] However, in existing technologies, ergothioneine and glycyrrhizin are mostly used alone in products. No research has been found on the combination of the two in a specific ratio to form a composition, nor has the synergistic effect of the two in terms of efficacy been recognized. Summary of the Invention

[0006] To address the above shortcomings, the present invention provides an ergothioneine composition and its application in skin whitening products.

[0007] the term:

[0008] In this invention, the term "L-ergothioneine" (ET) refers to a naturally occurring chiral sulfur-containing imidazole amino acid, which is the only bioactive configuration of ergothioneine. Its molecular structure contains a thiol group that forms a stable inner salt structure with the imidazole ring, endowing it with excellent antioxidant stability and non-oxidative self-consumption properties. It should be noted that this invention does not limit the source of L-ergothioneine. Whether obtained through natural extraction, microbial fermentation, chemical synthesis, or other preparation methods known in the art, as long as its chemical structure is consistent with the above definition of L-ergothioneine, it falls within the scope of L-ergothioneine referred to in this invention.

[0009] In this invention, the term "glabrazilin" is used in English. It refers to a natural isoflavone active ingredient extracted and isolated from plants of the genus *Glycyrrhiza*. Its chemical name is 4-[(3R)-3,4-dihydro-8,8-dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-3-yl]-1,3-benzenediol, glabrazilin, (R)-4-(3,4-dihydro-8,8-dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-3-yl)-1,3-benzenediol, with the molecular formula C2. 20 H 20 O4, with a molecular weight of 324.38, is a white to pale yellow crystalline powder. It is sparingly soluble in water but readily soluble in organic solvents such as ethanol and acetone. It possesses biological activities including inhibiting tyrosinase activity, anti-inflammatory, soothing, and antioxidant properties, and is one of the core active ingredients of the ergothioneine composition of this invention. This invention does not limit the source of glycyrrhizin; it can be extracted from the dried rhizomes of *Glycyrrhiza glabra*, *Glycyrrhiza uralensis*, and *Glycyrrhiza inflata*, or obtained through other preparation methods feasible in the art. As long as its chemical structure is consistent with the above definition of glycyrrhizin, it falls within the scope of glycyrrhizin referred to in this invention.

[0010] The technical solution of the present invention includes: On one hand, the present invention provides an ergothioneine composition, wherein the ergothioneine composition comprises glycyrrhizin and L-ergothioneine, wherein the mass ratio of glycyrrhizin and L-ergothioneine is 1:1-30.

[0011] Specifically, the mass ratio of glycyrrhizin to L-ergothioneine is 1:1-2, 1:2-3, 1:3-4, 1:4-5, 1:5-6, 1:6-7, 1:7-8, 1:8-9, 1:9-10, 1:10-11, 1:11-12, 1:12-13, 1:13-14, 1:14-15, 1:15-16, 1:16-17, 1:17-18, 1:18-19, 1:19-20, 1:20-21, 1:21-22, 1:22-23, 1:23-24, 1:24-25, 1:25-26, 1:26-27, 1:27-28, 1:28-29, or 1:29-30.

[0012] Preferably, the mass ratio of glycyrrhizin to L-ergothionein is 1:1-2, 1:2-3, 1:3-4, 1:4-5, 1:5-6, 1:6-7 or 1:7-8.

[0013] More preferably, the mass ratio of glycyrrhizin to L-ergothioneine is 1:8.

[0014] On the other hand, the present invention provides a method for preparing any of the above-mentioned ergothioneine compositions, the method comprising: mixing glycyrrhizin and L-ergothioneine in a mass ratio to obtain an ergothioneine composition.

[0015] In another aspect, the present invention provides a compositional formulation comprising any of the above-described ergothioneine compositions.

[0016] Specifically, the composition formulation further includes any one or more of the following: plant extracts, vitamins, bioactive peptides, enzymes, acids, polysaccharides, or mineral elements.

[0017] Preferably, the plant extracts include, but are not limited to, any one or more of the following: ginseng extract, grape seed extract, licorice extract, green tea extract, aloe vera extract, witch hazel extract, rosemary extract, centella asiatica extract, peony extract, angelica extract, coix seed extract, poria cocos extract, polygonum cuspidatum extract, mulberry bark extract, honeysuckle extract, orange peel extract, lemon extract, peach blossom extract, ginkgo leaf extract, wolfberry extract, rose extract, lavender extract, chamomile extract, atractylodes macrocephala extract, peony root bark extract, scutellaria baicalensis extract, astragalus membranaceus extract, angelica dahurica extract, bletilla striata extract, oat extract, eucommia ulmoides extract, kudzu root extract, polygonatum odoratum extract, rehmannia glutinosa extract, eleutherococcus senticosus extract, cornus officinalis extract, salvia miltiorrhiza extract, chrysanthemum extract, cinnamon extract, magnolia officinalis extract, schisandra chinensis extract, amomum villosum extract, and cistanche deserticola extract.

[0018] Specifically, the vitamins mentioned include fat-soluble vitamins and / or water-soluble vitamins.

[0019] Preferably, the fat-soluble vitamins include, but are not limited to, any one or more of vitamin A, vitamin D, vitamin E, or vitamin K; Preferably, the water-soluble microorganisms include, but are not limited to, any one or more of the following: vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B12, vitamin C, choline, or inositol.

[0020] Preferably, the bioactive peptides include, but are not limited to, any one or more of the following: collagen peptides, collagen tripeptides, elastin peptides, glutathione, casein phosphopeptides, hyaluronic acid hydrolysate peptides, ceramide peptides, soybean peptides, corn peptides, sea cucumber peptides, oyster peptides, bird's nest peptides, carnosine, or lactoferrin peptides.

[0021] Preferably, the enzymes include, but are not limited to, any one or more of the following: superoxide dismutase, catalase, glutathione peroxidase, bromelain, papain, and lysozyme.

[0022] Preferably, the acidic substances include, but are not limited to, any one or more of the following: vitamin A and its derivatives, vitamin C and its derivatives, fruit acids, salicylic acid, arbutin, tranexamic acid, kojic acid, ferulic acid, or azelaic acid.

[0023] Specifically, the polysaccharides include, but are not limited to, any one or more of the following: fungal polysaccharides, animal polysaccharides, plant polysaccharides, and algal polysaccharides.

[0024] Preferably, the fungal polysaccharides include, but are not limited to, any one or more of the following: Poria cocos polysaccharide, Tremella fuciformis polysaccharide, Enoki mushroom polysaccharide, Auricularia auricula-judae polysaccharide, Cordyceps sinensis polysaccharide, Phellinus linteus polysaccharide, and Trametes versicolor polysaccharide.

[0025] Preferably, the animal polysaccharide includes any one or more of the following: glycogen, chondroitin sulfate, hyaluronic acid, heparin, chitosan, chitin, or glycosaminoglycans; Preferably, the plant polysaccharides include any one or more of the following: cellulose, hemicellulose, pectin, inulin, konjac polysaccharide, astragalus polysaccharide, wolfberry polysaccharide, tea polysaccharide, kelp polysaccharide, or jujube polysaccharide; Preferably, the algal polysaccharide includes any one or more of green algal polysaccharides, red algal polysaccharides, or brown algal polysaccharides.

[0026] Preferably, the mineral elements include, but are not limited to, any one or more of the following: zinc, copper, iron, magnesium, calcium, or silicon.

[0027] In another aspect, the present invention provides the application of the above-mentioned ergothioneine composition or composition formulation, wherein the application includes any one or more of the following: (1) Application in the preparation of health products, food, cosmetics or pharmaceuticals with antioxidant effects; (2) Application in the preparation of cosmetics or pharmaceuticals with whitening effects.

[0028] Specifically, the dosage forms of the health products include, but are not limited to: tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids, or drops.

[0029] Specifically, the health products also include nutritionally acceptable additives.

[0030] Preferably, the nutritionally acceptable additives include, but are not limited to, one or more of the following: dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0031] Specifically, the food products mentioned include, but are not limited to: candy, soy milk, yogurt, canned food, biscuits, chocolate, pastries, cream, cheese, dairy products, milk powder, formula milk powder, ice cream, jam, fruit puree, candied fruit, preserved fruit, dried fruit, bread, egg rolls, protein drinks, solid beverages, lactic acid bacteria beverages, plant protein beverages, carbonated beverages, coffee, or puffed foods.

[0032] Preferably, the food includes human food or animal food.

[0033] Specifically, the food also includes nutritionally acceptable additives.

[0034] Preferably, the nutritionally acceptable additives include, but are not limited to, one or more of the following: dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0035] Specifically, the cosmetics include, but are not limited to, any one or more of the following: face cream, face mask, eye cream, neck cream, hand cream, body lotion, moisturizer, serum, toner, shampoo, conditioner, shower gel, or facial cleanser.

[0036] Specifically, the cosmetics also include excipients acceptable in the cosmetics industry.

[0037] Preferably, the excipients that can be added to the cosmetic include, but are not limited to, one or more of the following: moisturizers, thickeners, emollients, skin conditioning agents, emulsifiers, preservatives, softeners, lubricants, and stabilizers.

[0038] Specifically, the dosage forms of the medicine include, but are not limited to, any one or more of the following: tablets, capsules, injections, solutions, syrups, emulsions, suspensions, granules, ointments, suppositories, aerosols, and pills.

[0039] Specifically, the medicine also includes pharmaceutically additive excipients.

[0040] Preferably, the pharmaceutically additives include, but are not limited to, one or more of the following: wetting agents, emulsifiers, preservatives, antioxidants, buffers, diluents, lubricants, solutes, suspending agents, solubilizers, thickeners, stabilizers, sweeteners, and flavorings.

[0041] In another aspect, the present invention provides an antioxidant product comprising any of the ergothioneine compositions or formulations described above; the antioxidant product includes health products, food, cosmetics, or pharmaceuticals.

[0042] Preferably, the dosage form of the antioxidant product includes any one or more of solid dosage forms, semi-solid dosage forms, and liquid dosage forms.

[0043] In another aspect, the present invention provides a skin whitening product comprising any of the ergothioneine compositions or formulations described above; the skin whitening product includes cosmetics or pharmaceuticals.

[0044] Preferably, the dosage form of the whitening product includes any one or more of solid dosage forms, semi-solid dosage forms, and liquid dosage forms.

[0045] In another aspect, the present invention provides a method for anti-oxidation or whitening, the method comprising using any one or more of the ergothioneine composition, composition formulation, antioxidant product, and whitening product described in any of the preceding claims.

[0046] Specifically, the method includes administering to a subject any one or more of the ergothioneine composition, composition formulation, antioxidant product, and skin whitening product described above.

[0047] Preferably, the subject is a mammal.

[0048] More preferably, the subject is a human being.

[0049] The beneficial effects of this invention are as follows: The ergothioneine composition provided by this invention has three core effects: first, it can effectively reduce malondialdehyde (MDA) levels and exert excellent antioxidant effects; second, it can significantly inhibit tyrosinase activity and reduce melanin production from the source; and third, it can reduce the skin melanin index and achieve a whitening effect. It can be widely used in the preparation of cosmetics, health products, food and pharmaceuticals with antioxidant or whitening effects. Attached Figure Description

[0050] Figure 1 The results are for the antioxidant capacity measurement; in the figure... The difference between the representative and the blank control group was statistically significant (p<0.001). The group represented by #### had a significant difference from the blank control group (p<0.0001); the group represented by #### had a significant difference from the oxidative damage model control group (p<0.0001); and the group represented by $$$$ had a significant difference from the Example 1 group (p<0.0001).

[0051] Figure 2 The results show the ability to inhibit melanin and tyrosinase; in the figure... The results showed a significant difference between the representative and the blank control group (p<0.05). The representative showed a significant difference from the blank control group (p<0.01). The difference between the representative and the blank control group was statistically significant (p<0.001). The group represented by #### had a significant difference from the blank control group (p<0.0001); the group represented by #### had a significant difference from the model group (p<0.0001); and the group represented by $$$$ had a significant difference from the Example 1 group (p<0.0001).

[0052] Figure 3To verify the results of the melanin inhibition capacity assay in animal experiments; (Figure 1) The values ​​of ## and ## represent a significant difference from the blank control group (p<0.0001); the values ​​of ## and #### represent a significant difference from the model control group (p<0.01); the values ​​of #### represent a significant difference from the model control group (p<0.0001); and the values ​​of $$$ represent a significant difference from the Example 1 group (p<0.001). Detailed Implementation

[0053] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0054] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention are obtained through conventional commercial means.

[0055] Example 1 An ergothioneine composition comprising glycyrrhizin and L-ergothioneine, wherein the mass ratio of glycyrrhizin to L-ergothioneine in the composition is 1:8.

[0056] The composition is prepared by weighing glycyrrhizin and L-ergothioneine separately, mixing them evenly according to the mass ratio to obtain the composition.

[0057] Example 2 An ergothioneine composition comprising glycyrrhizin and L-ergothioneine in a mass ratio of 1:1. The preparation method of the composition is described in Example 1.

[0058] Example 3 An ergothioneine composition comprising glycyrrhizin and L-ergothioneine in a mass ratio of 1:30. The preparation method of the composition is described in Example 1.

[0059] Comparative Example 1 An ergothioneine composition comprising glycyrrhizin and L-ergothioneine in a mass ratio of 2:1. The preparation method of the composition is described in Example 1.

[0060] Comparative Example 2 Comparative Example 2 was glycyrrhizin.

[0061] Comparative Example 3 Comparative Example 3 was L-ergothioneine.

[0062] Experimental Example 1: Determination of Antioxidant Capacity HaCaT cells were harvested at 5 × 10⁻⁶. 5 Cells were seeded at 2 mL / well in 96-well plates and cultured for 24 h. A blank control group was treated with 100 μL of complete culture medium, while the other groups were treated with 4 mM H2O2 to construct an oxidative damage model. The positive control group was treated with 50 μL of vitamin A (prepared in serum-free medium to a concentration of 200 μg / mL). Examples 1-3 and Comparative Examples 1-3 were treated with 50 μL of the corresponding ergothioneine composition, glycyrrhizin, or L-ergothioneine (prepared in serum-free medium to a concentration of 100 μg / mL, respectively). Cells were cultured for another 24 h. Cells were then collected from each group and washed twice with PBS buffer. The MDA content in the supernatant was detected using an MDA detection kit.

[0063] The measurement results are as follows Figure 1 As shown in Table 1: Table 1

[0064] The test results show that the compositions of Examples 1-3 of the present invention can effectively reduce MDA levels, and the improvement effect is better than that of the positive control drug.

[0065] Experiment Example 2: Zebrafish Demonstration of the Ability to Inhibit Melanin and Tyrosinase 7 hpf zebrafish embryos were placed in a 12-well plate, with 25 normally developing embryos in each well. They were randomly divided into a blank group, a model group, a positive group, Example 1-Example 3 groups, and Comparative Example 1-Comparative Example 3 groups. Control group: Add an equal volume of fish embryo culture medium; Model group: 1.5 μM α-melanocyte-stimulating hormone (α-MSH) was added, along with an equal volume of fish embryo culture medium; Positive group: Add 1.5 μM α-MSH and 100 μg / mL kojic acid (kojic acid was dissolved in fish embryo culture medium before being added); Example 1 group: 1.5 μM α-MSH was added, along with 50 μg / mL of the ergothioneine composition from Example 1 (the ergothioneine composition was dissolved in fish embryo culture medium before being added). Example 2 group: 1.5 μM α-MSH was added, along with 50 μg / mL of the ergothioneine composition from Example 2 (the ergothioneine composition was dissolved in fish embryo culture medium before being added). Example 3 group: 1.5 μM α-MSH was added, along with 50 μg / mL of the ergothioneine composition from Example 3 (the ergothioneine composition was dissolved in fish embryo culture medium before being added). Comparative Example 1: 1.5 μM α-MSH was added, along with 50 μg / mL of the ergothioneine composition from Comparative Example 1 (the ergothioneine composition was dissolved in fish embryo culture medium before being added). Comparative Example 2: 1.5 μM α-MSH was added, along with 50 μg / mL of glabridin from Comparative Example 2 (glabridin was dissolved in fish embryo culture medium before being added). Comparative Example 3: 1.5 μM α-MSH was added, along with 50 μg / mL of L-ergothioneine from Comparative Example 3 (L-ergothioneine was dissolved in fish embryo culture medium before being added). Each group was divided into three parallel groups, with 3 mL of solution added to each well. The groups were incubated at 28±0.5℃, and the test solution was changed every 24 h. After 72 h, the zebrafish from each group were collected in 1.5 mL EP tubes, 150 μL of RIPA lysis buffer was added, and the zebrafish were homogenized using a handheld mini homogenizer. After thorough homogenization, the zebrafish were centrifuged at 4℃ and 12000 rpm for 10 min, the supernatant was discarded, and the precipitate was collected.

[0066] Immediately add 150 μL of 1N NaOH / 10% DMSO to each group of precipitates, lyse at 80℃ for 1 h, and determine the total melanin content using an ELISA reader at 450 nm absorbance (OD). Using the absorbance of the blank group as a control, calculate the relative melanin content in each group of cells. Protein concentrations of all samples were determined using a BCA kit, and melanin content was normalized based on protein concentration. The formula is as follows: Melanin content (%) = OD of drug-treated group / OD of blank group × 100%.

[0067] The model was established and drug administration was performed as described above. Zebrafish pellets were collected after 72 hours. The collected pellets were dissolved in PBS solution containing 1% Triton X-100, and after three freeze-thaw cycles at -80°C, the cells were centrifuged at 12,000 rpm for 10 minutes to obtain the cell supernatant. After protein quantification and normalization, 90 μL of cell supernatant and 10 μL of L-DOPA (10 mM) were added to a 96-well plate and incubated at 37°C for 1 hour. The absorbance at 405 nm was measured using a microplate reader. The relative content of tyrosinase in the cells was calculated using the blank control group. The protein concentration of all samples was determined using a BCA kit, and the tyrosinase activity was normalized based on the protein concentration. The formula is: Tyrosinase content (%) = OD drug group / OD blank group × 100%.

[0068] Results of the assay for the ability to inhibit melanin and tyrosinase are as follows: Figure 2As shown in Table 2: Table 2

[0069] The test results show that the compositions of Examples 1-3 of the present invention can effectively reduce the content of melanin and tyrosinase, and have a good ability to inhibit melanin and tyrosinase.

[0070] Experiment Example 3: Animal experiments to verify melanin inhibition ability Twenty-five female, healthy adult brown-yellow Hartly guinea pigs, weighing 250±20g, were divided into four groups: blank control group, model control group, Example 1 group, glycyrrhizin group, and L-ergothionein group, with five guinea pigs in each group.

[0071] In this study, guinea pigs in the model control group, Example 1 group, glycyrrhizin group, and L-ergothionein group underwent ultraviolet (UV) irradiation to develop a skin melanosis model: brown skin areas of guinea pigs were harvested, hair was removed, and the skin was irradiated with UVB at a wavelength of 310 nm, with a cumulative irradiation total of 5000 mJ / cm². 2 Irradiate once a day for 1 hour each time, for 7 days.

[0072] A closed spot treatment apparatus was used. 1 mL of the test drug (100 μg / mL of the ergothioneine composition from Example 1, 100 μg / mL of glycyrrhizin from Comparative Example 2, or 100 μg / mL of L-ergothioneine from Comparative Example 3) was placed inside the apparatus and brought into direct contact with the skin. The apparatus was then fixed in place, and the application time was 6 hours. After the test, residual test drug was removed with warm water. The above administration procedure was repeated once daily for 3 consecutive weeks. The model control group and the blank control group received 1 mL of 0.9% physiological saline each time. After the last administration, the animals were euthanized, and skin tissue was collected. The melanin index (MI) was then measured using a mexmeter.

[0073] MI measurement results as follows Figure 3 As shown in Table 3: Table 3

[0074] The test results show that the composition of the present invention can effectively reduce the melanin index.

[0075] The above detailed description is a specific illustration of one feasible embodiment of the present invention, and this embodiment is not intended to limit the patent scope of the present invention. It should be noted that all equivalent implementations or modifications made without departing from the present invention should be included within the scope of the technical solution of the present invention. Therefore, the protection scope of the present invention should be determined by the appended claims.

Claims

1. An ergothioneine composition, characterized in that, The ergothioneine composition comprises glycyrrhizin and L-ergothioneine, wherein the mass ratio of glycyrrhizin to L-ergothioneine is 1-15:1-30.

2. The ergothioneine composition according to claim 1, characterized in that, The mass ratio of glycyrrhizin and L-ergothioneine is 1:1-30.

3. The ergothioneine composition according to claim 1, characterized in that, The mass ratio of glycyrrhizin and L-ergothioneine is 1:1-8.

4. A method for preparing the ergothioneine composition according to any one of claims 1-3, characterized in that, The preparation method includes: mixing glycyrrhizin and L-ergothionein in a mass ratio to obtain an ergothionein composition.

5. A compositional formulation comprising the ergothioneine composition according to any one of claims 1-3.

6. The composition formulation according to claim 5, characterized in that, The composition formulation further includes any one or more of the following: plant extracts, vitamins, bioactive peptides, enzymes, acids, polysaccharides, or mineral elements.

7. The use of the ergothioneine composition according to any one of claims 1-3 or the composition formulation according to any one of claims 5-6, characterized in that, The applications include any one or more of the following: (1) Application in the preparation of health products, food, cosmetics or pharmaceuticals with antioxidant effects; (2) Application in the preparation of cosmetics or pharmaceuticals with whitening effects.

8. An antioxidant product, characterized in that, The antioxidant product comprises the ergothioneine composition according to any one of claims 1-3 or the composition formulation according to any one of claims 5-6; the antioxidant product includes health products, food, cosmetics or pharmaceuticals.

9. The antioxidant product according to claim 8, characterized in that, The dosage form of the antioxidant product includes any one or more of solid dosage forms, semi-solid dosage forms, and liquid dosage forms.

10. A skin whitening product, characterized in that, The whitening product comprises the ergothioneine composition according to any one of claims 1-3 or the composition formulation according to any one of claims 5-6; the whitening product includes cosmetics or pharmaceuticals.

11. The whitening product according to claim 10, characterized in that, The whitening product can be formulated in any one or more of the following forms: solid, semi-solid, and liquid.

Images